Biohaven Pharmaceutical Ownership
| BHVN Stock | USD 46.01 0.47 1.01% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 87.8 M | Current Value 94.4 M | Avarage Shares Outstanding 1.4 B | Quarterly Volatility 8.2 B |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Biohaven |
Biohaven Stock Ownership Analysis
About 87.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 9.37. Biohaven Pharmaceutical had not issued any dividends in recent years. Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Biohaven is traded on New York Stock Exchange in the United States. For more info on Biohaven Pharmaceutical Holding please contact Vlad Coric at 203 404 0410 or go to https://www.biohaven.com.Biohaven Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biohaven Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biohaven Pharmaceutical Holding backward and forwards among themselves. Biohaven Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biohaven Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.7 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.5 M | Perceptive Advisors Llc | 2024-09-30 | 1.5 M | Adage Capital Partners Gp Llc | 2024-09-30 | 1.5 M | Armistice Capital, Llc | 2024-09-30 | 1.2 M | Redmile Group, Llc | 2024-09-30 | 1 M | Schmeidler A R & Co Inc | 2024-09-30 | 1 M | Brown Advisory Holdings Inc | 2024-09-30 | 968.4 K | Vanguard Group Inc | 2024-09-30 | 7.8 M | Stifel Financial Corp | 2024-09-30 | 6.5 M |
Biohaven Pharmaceutical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biohaven Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biohaven Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biohaven Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biohaven Pharmaceutical Outstanding Bonds
Biohaven Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biohaven Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biohaven bonds can be classified according to their maturity, which is the date when Biohaven Pharmaceutical Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Biohaven Pharmaceutical Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify | |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 2nd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biohaven Stock
| 0.88 | VCNX | Vaccinex | PairCorr |
| 0.46 | DRMA | Dermata Therapeutics | PairCorr |
| 0.45 | VALN | Valneva SE ADR | PairCorr |
| 0.34 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.